KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Cost of Revenue (2016 - 2025)

NovoCure's Cost of Revenue history spans 12 years, with the latest figure at $9.3 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 72.23% year-over-year to $9.3 million; the TTM value through Dec 2025 reached $166.9 million, up 21.65%, while the annual FY2025 figure was $166.9 million, 21.65% up from the prior year.
  • Cost of Revenue for Q4 2025 was $9.3 million at NovoCure, down from $44.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $74.3 million in Q2 2025 and bottomed at -$9.2 million in Q4 2022.
  • The 5-year median for Cost of Revenue is $33.6 million (2024), against an average of $36.8 million.
  • The largest annual shift saw Cost of Revenue plummeted 130.86% in 2022 before it surged 746.02% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $29.7 million in 2021, then tumbled by 130.86% to -$9.2 million in 2022, then soared by 746.02% to $59.2 million in 2023, then tumbled by 43.46% to $33.5 million in 2024, then tumbled by 72.23% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Cost of Revenue are $9.3 million (Q4 2025), $44.7 million (Q3 2025), and $74.3 million (Q2 2025).